In recent developments, discussions have been underway between the central government and Zydus Cadila over the pricing of the coronavirus vaccine ZyCov-D.
According to reports, the proposed pricing of the three-dose jab is INR 1,900 that can be given to those above 12 years of age. Moreover, the government is negotiating for a reduction in price and a final decision on it is likely to be taken this week, as per reports in the PTI. Earlier last week, the government had said that the indigenously-developed, world's first DNA-based needle-free COVID-19 vaccine by Zydus Cadila will be introduced in the nationwide anti-coronavirus vaccination drive shortly.
Cadila Healthcare Ltd had earlier applied for the authorisation of the coronavirus vaccine ZyCoV-D on July 1, based on an efficacy rate of 66.6 per cent in a late-stage trial of more than 28,000 volunteers nationwide.
The vaccine by Cadila Healthcare, ZyCoV-D, would become the fifth vaccine cleared for use in the country after locally produced Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V and the US-made Moderna. Moreover, it will become the world’s first DNA vaccine to get the nod in any country. In addition, this is the first time any vaccine has been tested in the adolescent population in the 12-18 age group in India.
ALSO READ: UK govt. engages with India over recognition of vaccine certificate
Share
Tweet
